APLS
Apellis Pharmaceuticals Inc.
Price performance
Sep 16, 2026About
Company activity
15 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 05/14 | APLS | 8-K | Apellis Pharmaceuticals Merged with Biogen in $5.3 Billion Deal | — | — | — |
| 05/04 | APLS | 8-K | Apellis Pharmaceuticals Amends Executive Separation Plan Ahead of Merger | — | — | — |
| 03/31 | APLS | 8-K | Apellis Pharmaceuticals Announces Agreement to be Acquired by Biogen Inc. | — | — | — |
| 03/02 | APLS | 8-K | Apellis Pharmaceuticals Appoints Mikael Dolsten to Board of Directors | — | — | — |
| 01/12 | APLS | 8-K | Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Business Highlights | — | — | — |
| 07/01/25 | APLS | 8-K | Apellis Pharmaceuticals Announces Royalty Buy-Down Agreement with Sobi | — | — | — |
| 06/04/25 | APLS | 8-K | Apellis Pharmaceuticals Annual Meeting Voting Results Announced | — | — | — |
| 04/21/25 | APLS | 8-K | Apellis Pharmaceuticals Appoints Craig A. Wheeler to Board of Directors | — | — | — |
| 01/13/25 | APLS | 8-K | Apellis Pharmaceuticals Announces Preliminary 2024 Revenues and Key Executive Changes | — | — | — |
| 08/08/24 | APLS | 8-K | Apellis Pharmaceuticals Announces Positive Phase 3 Results for Pegcetacoplan in Rare Kidney Diseases | — | — | — |
| 06/05/24 | APLS | 8-K | Apellis Pharmaceuticals Holds Annual Meeting with Director Elections and Audit Approval | — | — | — |
| 05/14/24 | APLS | 8-K | Apellis Pharmaceuticals Enters into $475M Financing Agreement | — | — | — |
| 02/27/24 | APLS | 8-K | Apellis Pharmaceuticals Reports Q4 and FY 2023 Financial Results and Announces Capped Call Unwinding | — | — | — |
| 01/22/24 | APLS | 8-K | Apellis Pharmaceuticals Appoints New COO | — | — | — |
| 01/08/24 | APLS | 8-K | Apellis Pharmaceuticals Announces Preliminary 2023 Financial Results | — | — | — |
APLS filing record
Apellis Pharmaceuticals Inc. (APLS): 15 8-K filings summarized, the most recent on May 14, 2026.
What the 8-K filings said
- May 14, 2026 · high impact
Apellis Pharmaceuticals, Inc. has completed its merger with Biogen Inc., resulting in Apellis becoming a wholly owned subsidiary of Biogen. The merger, valued at approximately $5.3 billion, involved the exchange of Apellis' common stock for $41.00 per share in cash and contingent value rights (CVRs). The transaction…
Apellis Pharmaceuticals Merged with Biogen in $5.3 Billion Deal - May 4, 2026 · high impact
On April 28, 2026, Apellis Pharmaceuticals, Inc.'s compensation committee approved an amendment to its Executive Separation Benefits and Retention Plan. The amendment, effective upon the closing of the merger with Biogen Inc., accelerates the vesting of unvested rights for participants, including named executive…
Apellis Pharmaceuticals Amends Executive Separation Plan Ahead of Merger - Mar 31, 2026 · high impact
Apellis Pharmaceuticals, Inc. has entered into an Agreement and Plan of Merger with Biogen Inc. and Aspen Purchaser Sub, Inc., a wholly owned subsidiary of Biogen. Under the terms of the agreement, Biogen will acquire all outstanding shares of Apellis for $41.00 per share in cash, plus one contingent value right per…
Apellis Pharmaceuticals Announces Agreement to be Acquired by Biogen Inc. - Mar 2, 2026 · medium impact
On February 27, 2026, Apellis Pharmaceuticals, Inc. announced the election of Mikael Dolsten, M.D., Ph.D., to its Board of Directors, effective March 1, 2026. Dr. Dolsten, who is deemed 'independent' under Nasdaq rules, will receive compensation in the form of stock options and restricted stock units valued at…
Apellis Pharmaceuticals Appoints Mikael Dolsten to Board of Directors - Jan 12, 2026 · medium impact
Apellis Pharmaceuticals, Inc. announced preliminary U.S. net product revenues of approximately $689 million for the full year 2025. The company reported strong growth in demand for SYFOVRE and continued expansion of EMPAVELI in rare diseases. Apellis ended the year with approximately $466 million in cash and cash…
Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Business Highlights
SEC filings in the last five years
- 36 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 10-K/A